Thermo Fisher Scientific has finished the expansion of one of its manufacturing facilities for cell culture media, in Grand Island, New York, in the United States.
The facility offers redundant space for high-quality equipment and materials required for the development and mass manufacture of novel vaccines and biologic medicines.
The Grand Island expansion was announced earlier this year as part of its $650 million investment in these important medicines, including for COVID-19 vaccines, to ensure flexible, scalable, and dependable misprocessing production capacity.
The expansion increases the manufacturing space for Animal Origin Free (AOF) products by more than 45,000 square feet. This includes producing AOF Dry Powder Media (DPM) products and Thermo Fisher's Advanced Granulation Technology (AGT) format.
The additional space will enable process capabilities and equipment to provide production redundancy and reduce lead times for product manufacturing, which will speed up the research and production of life-saving biotherapeutics and vaccines.
The expansion is expected to add 100 employees across roles in R&D, operations, manufacturing, HR, engineering, and maintenance.
Thermo Fisher currently employs more than 1,600 people at the Grand Island site and more than 3,000 people across the state of New York.
|Thermo Fisher Scientific